AUTOMATED SCREENING WITH CONFIRMATION OF MECHANISM-BASED INACTIVATION OF CYP3A4, CYP2C9, CYP2C19, CYP2D6, AND CYP1A2 IN POOLED HUMAN LIVER MICROSOMES

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Drug Metabolism And Disposition

• Publication date

  2005-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/DMD.104.003475PMID 15860655
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data

  2004cited by this paper
• Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]- 4-[4-(trifluoromethyl)-2-pyridinyl]piperazine: kinetic characterization and evidence for apoprotein adduction.

  2004influential reference
• Validated assays for human cytochrome P450 activities.

  2004cited by this paper
• Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible.

  2004cited by this paper
• The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

  2003cited by this paper
• Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen.

  2003cited by this paper
• Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.

  2003cited by this paper
• Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein.

  2002cited by this paper
• Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine.

  2002cited by this paper
• N-OXIDATION OF DRUGS ASSOCIATED WITH IDIOSYNCRATIC DRUG REACTIONS

  2002cited by this paper
• Rhabdomyolysis and statin therapy: relevance to the elderly.

  2002cited by this paper
• A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry.

  2001influential reference
• Characterization of the selectivity and mechanism of cytochrome P450 inhibition by dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate.

  2001cited by this paper
• Optimizing Drug Development: Strategies to Assess Drug Metabolism/Transporter Interaction Potential—Toward a Consensus

  2001influential reference
• Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19.

  2001influential reference
• Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes

  2001cited by this paper
• Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission.

  2001cited by this paper
• Drug-Drug Interactions

  2001cited by this paper
• Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation.

  2000cited by this paper
• Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions.

  2000cited by this paper
• Coumarinic derivatives as mechanism-based inhibitors of α-chymotrypsin and human leukocyte elastase

  2000cited by this paper
• Coumarinic derivatives as mechanism-based inhibitors of alpha-chymotrypsin and human leukocyte elastase.

  2000cited by this paper
• Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.

  2000cited by this paper
• Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).

  1999cited by this paper
• Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.

  1999cited by this paper
• Drug–drug interactions of new active substances: mibefradil example

  1999influential reference
• Improved reliability of the rapid microtiter plate assay using recombinant enzyme in predicting CYP2D6 inhibition in human liver microsomes.

  1999influential reference
• Antiprogestin-Mediated Inactivation of Cytochrome P450 3A4

  1998cited by this paper
• Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A.

  1998cited by this paper
• Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450.

  1997cited by this paper
• Drug-drug interactions.

  1996cited by this paper
• Cisapride and fatal arrhythmia.

  1996cited by this paper
• Contemporary enzyme kinetics and mechanism

  1996cited by this paper
• Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs.

  1995cited by this paper
• Pharmacokinetic-Pharmacodynamic Relationships of H1-Antihistamines

  1995cited by this paper
• Characterization of the inhibition of P4501A2 by furafylline.

  1994cited by this paper
• Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid.

  1994influential reference
• Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline.

  1993influential reference
• Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds.

  1991cited by this paper
• Torsades de pointes occurring in association with terfenadine use.

  1990cited by this paper
• Introduction to mass spectrometry

  1986cited by this paper
• Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase.

  1962cited by this paper

• Recent advances in developing modified C14 side chain pleuromutilins as novel antibacterial agents.

  2024cites this paper
• Roles of human cytochrome P450 3A4/5 in dexamethasone 6β-hydroxylation mediated by liver microsomes and humanized liver in chimeric mice metabolically suppressed with azamulin.

  2023cites this paper
• Mechanistic Study of Icaritin-Induced Inactivation of Cytochrome P450 2C9

  2023cites this paper
• Structural characterization of the homotropic cooperative binding of azamulin to human cytochrome P450 3A5

  2022cites this paper
• Direct and Sequential Bioactivation of Pemigatinib to Reactive Iminium Ion Intermediates Culminates in Mechanism-Based Inactivation of Cytochrome P450 3A

  2022cites this paper
• Customizable Microfluidic Origami Liver‐on‐a‐Chip (oLOC)

  2022cites this paper
• Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib.

  2021cites this paper
• Infigratinib Is a Reversible Inhibitor and Mechanism-Based Inactivator of Cytochrome P450 3A4

  2021cites this paper
• Icotinib Induces Mechanism-Based Inactivation of Recombinant Human CYP3A4/5 Possibly via Heme Destruction by Ketene Intermediate

  2021cites this paper
• Inhibition of Caffeine Metabolism by Apiaceous and Rutaceae Families of Plant Products in Humans: In Vivo and In Vitro Studies

  2021cites this paper
• Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement

  2020cites this paper
• Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1.

  2020cites this paper
• Antibacterial properties and clinical potential of pleuromutilins.

  2019cites this paper
• Enzymes and Pathways of Kavain Bioactivation and Biotransformation.

  2019cites this paper
• Biomolecular Targets of Oxyprenylated Phenylpropanoids and Polyketides.

  2019cites this paper
• A strategy for early-risk predictions of clinical drug–drug interactions involving the GastroPlusTM DDI module for time-dependent CYP inhibitors

  2018cites this paper
• Amelioration of mechanism-based inactivation of CYP3A4 by a H-PGDS inhibitor.

  2018cites this paper
• Retrospective use of PBPK modelling to understand a clinical drug–drug interaction between dextromethorphan and GSK1034702

  2017influential citation
• A Perspective on the Kinetics of Covalent and Irreversible Inhibition

  2017cites this paper
• Risk Assessment Using Cytochrome P450 Time-Dependent Inhibition Assays at Single Time and Concentration in the Early Stage of Drug Discovery.

  2017cites this paper
• Metabolic activation and drug‐induced liver injury: in vitro approaches for the safety risk assessment of new drugs

  2016cites this paper
• In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity

  2016cites this paper
• Inhibition of Caffeine Metabolism in Humans by Furanocoumarin-Containing Plant Extracts: In Vivo and In Vitro Studies

  2016cites this paper
• Hydroxylation of 20-hydroxyvitamin D3 by human CYP3A4.

  2016cites this paper
• Metabolomics – an analytical strategy for identification of toxic mechanism of action

  2015cites this paper
• Perfluorononanoic acid in combination with 14 chemicals exerts low-dose mixture effects in rats

  2015cites this paper
• Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A.

  2015cites this paper
• Integrative Systems Biology Applied to Toxicology

  2015cites this paper
• Drug‐drug interactions in pharmacologic management of gastroparesis

  2015cites this paper
• Development of a Rapid and Cost Effective Assay for the Screening of Reversible Cytochrome P450 Inhibition in Parallel with Cyp3a4 Metabolism-Dependent Inhibition Using Recombinant Proteins

  2015cites this paper
• In Vitro Approaches to Study Drug–Drug Interactions

  2014cites this paper
• Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism in vitro

  2014cites this paper
• Coupling liquid chromatography/mass spectrometry detection with microfluidic droplet array for label-free enzyme inhibition assay.

  2014cites this paper
• β-Amyrin biosynthesis: the critical role of steric volume at C-19 of 2,3-oxidosqualene for its correct folding to generate the pentacyclic scaffold.

  2014cites this paper
• Drug Interaction Assessment Strategies: Small Molecules versus Therapeutic Proteins

  2013cites this paper
• Effect of Solvents on the Time-Dependent Inhibition of CYP3A4 and the Biotransformation of AZD3839 in Human Liver Microsomes and Hepatocytes

  2013cites this paper
• Evaluation of Drug–Drug Interaction Risk with PBPK Models

  2012cites this paper
• Interactions between phytochemicals from traditional Chinese medicines and human cytochrome P450 enzymes.

  2012cites this paper
• Modeling Chemical Interaction Profiles: II. Molecular Docking, Spectral Data-Activity Relationship, and Structure-Activity Relationship Models for Potent and Weak Inhibitors of Cytochrome P450 CYP3A4 Isozyme

  2012cites this paper
• Molecular analysis and modeling of inactivation of human CYP2D6 by four mechanism based inactivators.

  2012cites this paper
• Progress Curve Mechanistic Modeling Approach for Assessing Time-Dependent Inhibition of CYP3A4

  2012cites this paper
• Microsoft Word-39738606-file00.docx

  2012cites this paper
• Technical Challenges and Recent Advances of Implementing Comprehensive ADMET Tools in Drug Discovery

  2012cites this paper
• Assessment of drug-drug interactions caused by metabolism-dependent cytochrome P450 inhibition.

  2012cites this paper
• In Vitro Liver Systems to Study Induction/Inhibition: Prediction of In Vivo Metabolism and Drug–Drug Interactions

  2012cites this paper
• The current status of time dependent CYP inhibition assay and in silico drug-drug interaction predictions.

  2012cites this paper
• Sequential Metabolism of AMG 487, a Novel CXCR3 Antagonist, Results in Formation of Quinone Reactive Metabolites That Covalently Modify CYP3A4 Cys239 and Cause Time-Dependent Inhibition of the Enzyme

  2012cites this paper
• Bioactivation of herbal constituents: simple alerts in the complex system

  2011cites this paper
• Microsoft Word-74715577-file00

  2011cites this paper
• CYP3A TIME DEPENDENT INHIBITION RISK ASSESSMENT VALIDATED WITH 400 REFERENCE DRUGS

  2011cites this paper
• Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development.

  2011cites this paper
• Combination of GSH Trapping and Time-Dependent Inhibition Assays as a Predictive Method of Drugs Generating Highly Reactive Metabolites

  2011cites this paper
• Microsoft Word-22828359-file00.docx

  2011cites this paper
• CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference Drugs

  2011influential citation
• Mechanism-based inhibition of CYP2C8 by gemfibrozil in humans : characterisation of time and dose relationships

  2011cites this paper
• Combination of glutathione trapping and time-dependent inhibition assays as a predictive method drugs generating highly reactive metabolites

  2011cites this paper
• Discovery of TRPV1 antagonist ABT-116.

  2010cites this paper
• Characterization of Cytochrome P450 Mechanism-Based Inhibition

  2010cites this paper
• CYP Inhibition-Mediated Drug-Drug Interactions

  2010cites this paper
• Herbal interactions with anticancer drugs: mechanistic and clinical considerations.

  2010cites this paper
• Cell-based assays: fuelling drug discovery

  2010cites this paper
• Toxicology, Safety and Herb–drug Interactions in Cancer Therapy

  2010cites this paper
• In Vivo Evaluation of Drug-Drug Interaction via Mechanism-Based Inhibition by Macrolide Antibiotics in Cynomolgus Monkeys

  2009cites this paper
• Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.

  2009cites this paper
• Comprehensive assessment of ADMET risks in drug discovery.

  2009cites this paper
• Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development

  2009cites this paper
• Chapter 26 Mechanism-Based Inhibition of CYP3A4 and Other Cytochromes P450

  2009cites this paper
• The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America

  2009influential citation
• Bioluminescent assays for ADMET

  2008cites this paper
• A generic method to detect electrophilic intermediates using isotopic pattern triggered data-dependent high-resolution accurate mass spectrometry.

  2008cites this paper
• Applying automation in early drug discovery: lessons learnt and future perspectives An issue that the drug discovery industry has faced over the past

  2008cites this paper
• Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.

  2008cites this paper
• Cytochrome P450s: Drug–Drug Interactions

  2008cites this paper
• Hepatic Bioactivation and Drug-Induced Liver Injury

  2008cites this paper
• The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo

  2008cites this paper
• In vitro approaches to investigate mechanism-based inactivation of CYP enzymes

  2007cites this paper
• Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update.

  2007cites this paper
• The pivotal role of hepatocytes in drug discovery.

  2007cites this paper
• Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring

  2007cites this paper
• Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis.

  2007cites this paper
• Metabolite identification by data-dependent accurate mass spectrometric analysis at resolving power of 60,000 in external calibration mode using an LTQ/Orbitrap.

  2007cites this paper
• The Evolving Role of Drug Metabolism in Drug Discovery and Development

  2007cites this paper
• Time-dependent CYP inhibition

  2007cites this paper
• Toxicological Significance of Mechanism-Based Inactivation of Cytochrome P450 Enzymes by Drugs

  2007cites this paper
• Risk Assessment for Drug-Drug Interaction Caused by Metabolism-Based Inhibition of CYP3A Using Automated in Vitro Assay Systems and Its Application in the Early Drug Discovery Process

  2007cites this paper
• Pharmacokinetic Interactions with Thiazolidinediones

  2007cites this paper
• In vitro ADME medium/high-throughput screening in drug preclinical development.

  2006cites this paper
• Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.

  2006cites this paper
• Drug withdrawals and the lessons within.

  2006cites this paper
• EVALUATION OF TIME-DEPENDENT CYTOCHROME P450 INHIBITION USING CULTURED HUMAN HEPATOCYTES

  2006cites this paper
• Structure-Activity Relationship and Elucidation of the Determinant Factor(s) Responsible for the Mechanism-Based Inactivation of Cytochrome P450 2B6 by Substituted Phenyl Diaziridines

  2006cites this paper
• Covalent inhibitors of human cytochrome P450 3A4: research advances and future perspectives

  year unknowncites this paper